Table 1 Demographic and clinical characteristics of the our patient cohort at baseline and after 3, 6, and 12 months (M) of nintedanib treatment.

Healthy controls (n = 6)

Age, years

48.66 ± 4.18

-

-

-

Gender, n. (%)

 Female

3 (50)

-

-

-

  Age, years

46.66 ± 5.03

-

-

-

 Male

3 (50)

-

-

-

  Age, years

50.66 ± 2.52

-

-

-

Patients (n = 19)

Age, years

68.99 ± 10.32

-

-

-

Gender, n. (%)

 Female

11 (58)

-

-

-

  Age, years

72.23 ± 7.80

-

-

-

 Male

8 (42)

-

-

-

  Age, years

64.15 ± 12.20

-

-

-

Body mass index (kg/m²)

30.01 ± 4.94

-

-

-

Smoking status, n. (%)

 Yes

9 (47)

-

-

-

 No

10 (53)

-

-

-

Primary disease, n. (%)

 SSc-ILD

1 (5.3)

-

-

-

 NSIP

3 (15.6)

-

-

-

 RA-ILD

4 (21)

-

-

-

 ASyS-ILD

1 (5.3)

-

-

-

 CTD-ILD

1 (5.3)

-

-

-

 HP-ILD

5 (26.3)

-

-

-

 DIP-ILD

1 (5.3)

-

-

-

 Other ILD

3 (15.9)

-

-

-

Most frequent comorbidities, n. (%)

 Chronic atrial fibrillation

1 (5.3)

-

-

-

 Chronic obstr. bronchopathy

3 (15.6)

-

-

-

 Arterial hypertension

9 (47)

-

-

-

 Obstr. Sleep Apnea Syndrome

1 (5.3)

-

-

-

 Chronic renal failure

1 (5.3)

-

-

-

 Asthma

1 (5.3)

-

-

-

 Oncology

1 (5.3)

-

-

-

FVC

 mL

1910 ± 155

1923 ± 641

1918 ± 799

2031 ±

180

 % of predicted

73.21 ± 11.8

69.16 ± 10.45

77.21 ± 16.87

82.64 ± 13.11

DLCO

 mL

8.43 ± 1.92

8.58 ± 2.13

6.95 ± 2.16

9.13 ± 1.55

 % of predicted

40.63 ± 3.59

38.33 ± 3.25

33.71 ± 8.43

38.00 ± 5.89